Encapsulation and delivery of phage as a novel method for gut flora manipulation in situ: A review

Yang, Yufan; Du, Hongwu; Zou, Geng; Song, Zhiyong; Zhou, Yang; Li, Hao; Tan, Chen; Chen, Huanchun; Fischetti, Vincent A.; Li, Jinquan

doi:10.1016/j.jconrel.2022.11.048

Cited by 21 publications

(18 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(B) Administered phages actively diminish the population of pathogenic bacteria, eliminate harmful bacterial genes, and mitigate the absorption of detrimental metabolites in situ . [Adapted from ( 82 , 83 )].…”

Section: Interaction Between Microbiota and Bacteriophages In Ibdmentioning

confidence: 99%

Advances and optimization strategies in bacteriophage therapy for treating inflammatory bowel disease

Li,

Duan

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

In the advancement of Inflammatory Bowel Disease (IBD) treatment, existing therapeutic methods exhibit limitations; they do not offer a complete cure for IBD and can trigger adverse side effects. Consequently, the exploration of novel therapies and multifaceted treatment strategies provides patients with a broader range of options. Within the framework of IBD, gut microbiota plays a pivotal role in disease onset through diverse mechanisms. Bacteriophages, as natural microbial regulators, demonstrate remarkable specificity by accurately identifying and eliminating specific pathogens, thus holding therapeutic promise. Although clinical trials have affirmed the safety of phage therapy, its efficacy is prone to external influences during storage and transport, which may affect its infectivity and regulatory roles within the microbiota. Improving the stability and precise dosage control of bacteriophages—ensuring robustness in storage and transport, consistent dosing, and targeted delivery to infection sites—is crucial. This review thoroughly explores the latest developments in IBD treatment and its inherent challenges, focusing on the interaction between the microbiota and bacteriophages. It highlights bacteriophages’ potential as microbiome modulators in IBD treatment, offering detailed insights into research on bacteriophage encapsulation and targeted delivery mechanisms. Particular attention is paid to the functionality of various carrier systems, especially regarding their protective properties and ability for colon-specific delivery. This review aims to provide a theoretical foundation for using bacteriophages as microbiome modulators in IBD treatment, paving the way for enhanced regulation of the intestinal microbiota.

show abstract

Section: Interaction Between Microbiota and Bacteriophages In Ibdmentioning

confidence: 99%

Advances and optimization strategies in bacteriophage therapy for treating inflammatory bowel disease

Li,

Duan

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…[ 94 ] One of the reasons for this phenomenon is that the temperature change will cause the inactivation of phage protein, thereby leading to structural damage and stability reduction. [ 95 ] The influence of pH value is similar. [ 96 ] Alkali cations including Li + , Na + , K + , and Mg 2+ can prevent phages from inactivation under harsh conditions.…”

Section: Characteristics Of Phages‐based Carriersmentioning

confidence: 99%

Recent Progress in Phage‐Based Nanoplatforms for Tumor Therapy

Li,

Peng,

Feng

et al. 2023

Small

View full text Add to dashboard Cite

Nanodrug delivery systems have demonstrated a great potential for tumor therapy with the development of nanotechnology. Nonetheless, traditional drug delivery systems are faced with issues such as complex synthetic procedures, low reproducibility, nonspecific distribution, impenetrability of biological barrier, systemic toxicity, etc. In recent years, phage‐based nanoplatforms have attracted increasing attention in tumor treatment for their regular structure, fantastic carrying property, high transduction efficiency and biosafety. Notably, therapeutic or targeting peptides can be expressed on the surface of the phages through phage display technology, enabling the phage vectors to possess multifunctions. As a result, the drug delivery efficiency on tumor will be vastly improved, thereby enhancing the therapeutic efficacy while reducing the side effects on normal tissues. Moreover, phages can overcome the hindrance of biofilm barrier to elicit antitumor effects, which exhibit great advantages compared with traditional synthetic drug delivery systems. Herein, this review not only summarizes the structure and biology of the phages, but also presents their potential as prominent nanoplatforms against tumor in different pathways to inspire the development of effective nanomedicine.

show abstract

“…Due to denaturation of phage capsid proteins and nucleic acid, phages can lose their activity under different physico‐chemical conditions, such as high temperature, enzymes, very high or especially low pH values (Jończyk‐Matysiak et al, 2019). Moreover, in the oral phage therapy for animals, the effectiveness of phage may reduce or entirely lost during their passage through the gastrointestinal tract, due to the presence of digestive conditions like high acidity, digestive enzymes, and bile salts (Jończyk‐Matysiak et al, 2019; Ma et al, 2008; Yang et al, 2023). The highly acidic environment of the stomach may cause denaturation of phage proteins and nucleic acids, and the presence of digestive enzymes such as pepsin may cause hydrolysis of proteins and increase acid permeability.…”

Section: Introductionmentioning

confidence: 99%

“…The highly acidic environment of the stomach may cause denaturation of phage proteins and nucleic acids, and the presence of digestive enzymes such as pepsin may cause hydrolysis of proteins and increase acid permeability. As a result, the number of viable phages decreases (Yang et al, 2023).…”

mentioning

confidence: 99%

Encapsulation of SE‐P47 phage specific to SalmonellaEnteritidis and evaluation of its stability

Koçer Alaşalvar,

Yıldırım

2024

Journal of Food Safety

View full text Add to dashboard Cite

This study was conducted to encapsulate the bacteriophage SE‐P47 target to Salmonella Enteritidis by extrusion method and to examine its stability. Screening and optimization of effective factors in the encapsulation process were performed using fractional factorial design and face‐centered central composite design, respectively. The optimum Na‐alginate concentration and the ratio of coating material to phage for the encapsulation of SE‐P47 phage were 1.5% (v/v) and 2:1, respectively. At the optimum encapsulation point, the highest encapsulation efficiency (98.52%), smallest capsule size (1.28 mm), and highest phage titer were achieved. When exposed to heat treatment at 80°C for 30 min, pH 2 and simulated gastric fluid (pH 2.0) for 120 min, the encapsulated phage maintained almost its stability, but the free (non‐encapsulated) phage almost lost its activity. Phage release from beads in simulated intestinal fluid reached 100% in 4 h. In addition, free and encapsulated phage completely maintained their activity for 12 months at 4 and 25°C. The Salmonella phage encapsulated in this study exhibits high stability in harsh conditions. Thus, this encapsulated phage has the potential to be used as a biocontrol agent or therapeutic purposes in the food chain.

show abstract

Encapsulation and delivery of phage as a novel method for gut flora manipulation in situ: A review

Cited by 21 publications

References 122 publications

Advances and optimization strategies in bacteriophage therapy for treating inflammatory bowel disease

Advances and optimization strategies in bacteriophage therapy for treating inflammatory bowel disease

Recent Progress in Phage‐Based Nanoplatforms for Tumor Therapy

Encapsulation of SE‐P47 phage specific to SalmonellaEnteritidis and evaluation of its stability

Contact Info

Product

Resources

About